Korean J Gastroenterol.  2023 Oct;82(4):206-208. 10.4166/kjg.2023.104.

PD-L2-RGMb, Expected as a Target in Overcoming Immunotherapy Resistance

• Kim JH

• KMID: 2547293
• DOI: http://doi.org/10.4166/kjg.2023.104

Figure

• 

  Fig. 1 The binding between PD-L1 and PD-L2 expressed on the surface of antigen-presenting cells and PD-1 and RGMb expressed on the T cell surface. The figure was Created with BioRender.com.

Reference

1. Park JS, Gazzaniga FS, Wu M, et al. 2023; Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance. Nature. 617:377–385. DOI: 10.1038/s41586-023-06026-3. PMID: 37138075.

2. Ribas A, Wolchok JD. 2018; Cancer immunotherapy using checkpoint blockade. Science. 359:1350–1355. DOI: 10.1126/science.aar4060. PMID: 29567705. PMCID: PMC7391259.

3. Sun C, Mezzadra R, Schumacher TN. 2018; Regulation and function of the PD-L1 checkpoint. Immunity. 48:434–452. DOI: 10.1016/j.immuni.2018.03.014. PMID: 29562194. PMCID: PMC7116507.

4. Chen S, Zhang Z, Zheng X, et al. 2021; Response efficacy of PD-1 and PD-L1 inhibitors in clinical trials: A systematic review and meta-analysis. Front Oncol. 11:562315. DOI: 10.3389/fonc.2021.562315. PMID: 33937012. PMCID: PMC8085334.

5. Davar D, Dzutsev AK, McCulloch JA, et al. 2021; Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 371:595–602. DOI: 10.1126/science.abf3363. PMID: 33542131. PMCID: PMC8097968.

6. Baruch EN, Youngster I, Ben-Betzalel G, et al. 2021; Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 371:602–609. DOI: 10.1126/science.abb5920. PMID: 33303685.